Premium
Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress
Author(s) -
Lin ChihWei,
Lee JenYi,
Tsao YeouPing,
Shen ChePiao,
Lai HungCheng,
Chen ShowLi
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10759
Subject(s) - listeria monocytogenes , immune system , biology , ctl* , cytotoxic t cell , cd8 , intracellular parasite , microbiology and biotechnology , vaccination , immunity , immunology , recombinant dna , virology , in vitro , gene , bacteria , biochemistry , genetics
Abstract Listeria monocytogenes is a Gram‐positive, facultative intracellular bacterium with the ability to present secreted proteins to the major histocompatibility complex class I pathway to stimulate cell‐mediated immune response. In our study, we constructed the recombinant L. monocytogenes encoding human papillomavirus type 16 E7 gene (rLM‐E7). When orally administered to syngeneic mice, rLM‐E7 could induce a cytotoxic T‐lymphocyte (CTL) response. Furthermore, in vitro flow cytometric assay and in vivo immune deficiency assays showed that rLM‐E7 could prevent and eradicate tumor growth via CD8 + ‐dependent CTLs. Hence, the potency of rLM‐E7 as a therapeutic vaccine for cervical cancer is the result of the induction E7‐specific cell‐mediated immunity by L. monocytogenes . In addition to potency, this vaccine also offers ease of administration and reduced cost of production compared with other vaccines formulated for injection. Thus, L. monocytogenes encoding HPV‐16 E7 may be a useful oral vaccine for cervical cancer treatment. © 2002 Wiley‐Liss, Inc.